BioCentury | Apr 22, 2020
Product Development

FDA clears LabCorp’s COVID-19 home collection kits as Congress looks to bolster testing with $25B

LabCorp became the first diagnostic company to have an at-home collection kit for COVID-19 authorized by FDA, a month after the agency cleared its lab PCR test for the novel coronavirus. FDA also gave a...
BioCentury | Nov 11, 2019
Clinical News

DxTerity type I interferon biomarker study, launch bolsters lupus patient stratification

Data supporting the commercial launch of DxTerity’s type I interferon gene expression test in systemic lupus erythematosus (SLE) could lower barriers to signal detection in clinical trials by identifying patients who stand to benefit most...
BioCentury | Aug 21, 2019
Financial News

Oncorus raises $79.5M series B with eye on global development

Nearly half a dozen Korean investment groups joined Oncorus' $79.5 million series B round as part of the company's long-range plan to take its oncolytic virus technology global. Cowen Healthcare Investments and Perceptive Advisors led...
BioCentury | Mar 1, 2019
Product Development

Prostate cancer disrupted

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades. The launch of generic abiraterone means next generation anti-androgens...
BioCentury | Sep 21, 2018
Clinical News

Progenics' prostate cancer imaging agent meets specificity endpoint in Phase III

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) said SPECT/CT imaging with its 99mTc-MIP-1404 (1404, F-1311) imaging agent met the co-primary endpoint of specificity but missed the co-primary endpoint of sensitivity in a Phase III trial to detect low-grade...
BioCentury | Sep 11, 2018
Politics & Policy

ASCO fears CMS proposals 'endanger' access to cancer care

The American Society of Clinical Oncology voiced concerns in a comment letter that CMS's proposed changes to Medicare Part B payment policies for 2019 would "endanger" patient access to cancer care. It urged CMS to...
BioCentury | Aug 10, 2018
Clinical News

Audentes reports Phase I/II muscle biopsy data for myopathy gene therapy

Audentes Therapeutics Inc. (NASDAQ:BOLD) reported data from its 24-week muscle biopsy analyses of the first dose cohort and said an IDMC recommended proceeding to the second dose cohort of the Phase I/II ASPIRO trial evaluating...
BioCentury | Aug 3, 2018
Targets & Mechanisms

Oxitope’s oxidation play

A trio of papers from a UCSD group has found a connection between oxidized lipids and inflammation in atherosclerosis, osteoporosis and ischemia injury, breathing new life into the once popular “oxidation hypothesis” of atherosclerosis. The...
BioCentury | Jul 13, 2018
Clinical News

Cytokinetics' SMA candidate improves time to muscle fatigue in Phase II

Cytokinetics Inc. (NASDAQ:CYTK) reported data from ambulatory patients with spinal muscular atrophy (SMA) in a Phase II trial showing that reldesemtiv led to dose-dependent increases in time to muscle fatigue from baseline to week eight...
BioCentury | Jul 12, 2018
Product R&D

All-in-one viruses

Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at a time to tumor cells...
Items per page:
1 - 10 of 122